Daniel B Horton1,2, Karen B Onel3,4, Timothy Beukelman3,4, Sarah Ringold3,4. 1. From the Division of Pediatric Rheumatology, Department of Pediatrics, Rutgers Robert Wood Johnson Medical School, Institute for Health, Health Care Policy and Aging Research, Rutgers Biomedical and Health Sciences, New Brunswick, New Jersey; Division of Pediatric Rheumatology, Department of Pediatrics, Hospital for Special Surgery, Weill Cornell Medical College, New York, New York; Division of Pediatric Rheumatology, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama; Seattle Children's Hospital and Research Institute, University of Washington School of Medicine, Seattle, Washington, USA. daniel.horton@rutgers.edu. 2. D.B. Horton, MD, MSCE, Assistant Professor of Pediatrics, Division of Pediatric Rheumatology, Department of Pediatrics, Rutgers Robert Wood Johnson Medical School, Institute for Health, Health Care Policy and Aging Research, Rutgers Biomedical and Health Sciences; K.B. Onel, MD, Chief, Division of Pediatric Rheumatology, Department of Pediatrics, Hospital for Special Surgery, Weill Cornell Medical College; T. Beukelman, MD, MSCE, Associate Professor, Division of Pediatric Rheumatology, Department of Pediatrics, University of Alabama at Birmingham; S. Ringold, MD, MS, Assistant Professor, Seattle Children's Hospital, University of Washington School of Medicine. daniel.horton@rutgers.edu. 3. From the Division of Pediatric Rheumatology, Department of Pediatrics, Rutgers Robert Wood Johnson Medical School, Institute for Health, Health Care Policy and Aging Research, Rutgers Biomedical and Health Sciences, New Brunswick, New Jersey; Division of Pediatric Rheumatology, Department of Pediatrics, Hospital for Special Surgery, Weill Cornell Medical College, New York, New York; Division of Pediatric Rheumatology, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama; Seattle Children's Hospital and Research Institute, University of Washington School of Medicine, Seattle, Washington, USA. 4. D.B. Horton, MD, MSCE, Assistant Professor of Pediatrics, Division of Pediatric Rheumatology, Department of Pediatrics, Rutgers Robert Wood Johnson Medical School, Institute for Health, Health Care Policy and Aging Research, Rutgers Biomedical and Health Sciences; K.B. Onel, MD, Chief, Division of Pediatric Rheumatology, Department of Pediatrics, Hospital for Special Surgery, Weill Cornell Medical College; T. Beukelman, MD, MSCE, Associate Professor, Division of Pediatric Rheumatology, Department of Pediatrics, University of Alabama at Birmingham; S. Ringold, MD, MS, Assistant Professor, Seattle Children's Hospital, University of Washington School of Medicine.
Abstract
OBJECTIVE: To assess the attitudes and strategies of pediatric rheumatology clinicians toward withdrawing medications for children with clinically inactive juvenile idiopathic arthritis (JIA). METHODS: Members of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) completed an anonymous electronic survey on decision making and approaches for withdrawing medications for inactive nonsystemic JIA. Data were analyzed using descriptive statistics. RESULTS: Of 388 clinicians in CARRA, 124 completed surveys (32%), predominantly attending pediatric rheumatologists. The most highly ranked factors in decision making for withdrawing medications were the duration of clinical inactivity, drug toxicity, duration of prior activity, patient/family preferences, joint damage, and JIA category. Diagnoses of rheumatoid factor-positive polyarthritis and persistent oligoarthritis made respondents less likely and more likely, respectively, to withdraw JIA medications. Three-quarters of respondents waited for 6-12 months of inactive disease before stopping methotrexate (MTX) or biologics, but preferences varied. There was also considerable variability in the strategies used to reduce, taper, or stop medications for clinically inactive JIA; most commonly, clinicians reported slow medication tapers lasting at least 2 months. For children receiving combination MTX-biologic therapy, 63% of respondents preferred stopping MTX first. Most clinicians reported using imaging only seldom or sometimes to guide decision making, but most were also reluctant to withdraw medications in the presence of asymptomatic imaging abnormalities suggestive of subclinical inflammation. CONCLUSION: Considerable variability exists among pediatric rheumatology clinicians regarding when and how to withdraw medications for children with clinically inactive JIA. More research is needed to identify the most effective approaches to withdraw medications and predictors of outcomes.
OBJECTIVE: To assess the attitudes and strategies of pediatric rheumatology clinicians toward withdrawing medications for children with clinically inactive juvenile idiopathic arthritis (JIA). METHODS: Members of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) completed an anonymous electronic survey on decision making and approaches for withdrawing medications for inactive nonsystemic JIA. Data were analyzed using descriptive statistics. RESULTS: Of 388 clinicians in CARRA, 124 completed surveys (32%), predominantly attending pediatric rheumatologists. The most highly ranked factors in decision making for withdrawing medications were the duration of clinical inactivity, drug toxicity, duration of prior activity, patient/family preferences, joint damage, and JIA category. Diagnoses of rheumatoid factor-positive polyarthritis and persistent oligoarthritis made respondents less likely and more likely, respectively, to withdraw JIA medications. Three-quarters of respondents waited for 6-12 months of inactive disease before stopping methotrexate (MTX) or biologics, but preferences varied. There was also considerable variability in the strategies used to reduce, taper, or stop medications for clinically inactive JIA; most commonly, clinicians reported slow medication tapers lasting at least 2 months. For children receiving combination MTX-biologic therapy, 63% of respondents preferred stopping MTX first. Most clinicians reported using imaging only seldom or sometimes to guide decision making, but most were also reluctant to withdraw medications in the presence of asymptomatic imaging abnormalities suggestive of subclinical inflammation. CONCLUSION: Considerable variability exists among pediatric rheumatology clinicians regarding when and how to withdraw medications for children with clinically inactive JIA. More research is needed to identify the most effective approaches to withdraw medications and predictors of outcomes.
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: Jaime Guzman; Kiem Oen; Lori B Tucker; Adam M Huber; Natalie Shiff; Gilles Boire; Rosie Scuccimarri; Roberta Berard; Shirley M L Tse; Kimberly Morishita; Elizabeth Stringer; Nicole Johnson; Deborah M Levy; Karen Watanabe Duffy; David A Cabral; Alan M Rosenberg; Maggie Larché; Paul Dancey; Ross E Petty; Ronald M Laxer; Earl Silverman; Paivi Miettunen; Anne-Laure Chetaille; Elie Haddad; Kristin Houghton; Lynn Spiegel; Stuart E Turvey; Heinrike Schmeling; Bianca Lang; Janet Ellsworth; Suzanne Ramsey; Alessandra Bruns; Sarah Campillo; Susanne Benseler; Gaëlle Chédeville; Rayfel Schneider; Rae Yeung; Ciarán M Duffy Journal: Ann Rheum Dis Date: 2014-05-19 Impact factor: 19.103
Authors: Jaime Guzman; Kiem Oen; Adam M Huber; Karen Watanabe Duffy; Gilles Boire; Natalie Shiff; Roberta A Berard; Deborah M Levy; Elizabeth Stringer; Rosie Scuccimarri; Kimberly Morishita; Nicole Johnson; David A Cabral; Alan M Rosenberg; Maggie Larché; Paul Dancey; Ross E Petty; Ronald M Laxer; Earl Silverman; Paivi Miettunen; Anne-Laure Chetaille; Elie Haddad; Kristin Houghton; Lynn Spiegel; Stuart E Turvey; Heinrike Schmeling; Bianca Lang; Janet Ellsworth; Suzanne E Ramsey; Alessandra Bruns; Johannes Roth; Sarah Campillo; Susanne Benseler; Gaëlle Chédeville; Rayfel Schneider; Shirley M L Tse; Roxana Bolaria; Katherine Gross; Brian Feldman; Debbie Feldman; Bonnie Cameron; Roman Jurencak; Jean Dorval; Claire LeBlanc; Claire St Cyr; Michele Gibbon; Rae S M Yeung; Ciarán M Duffy; Lori B Tucker Journal: Ann Rheum Dis Date: 2015-05-18 Impact factor: 19.103
Authors: Robert Hemke; Mario Maas; Mira van Veenendaal; Koert M Dolman; Marion A J van Rossum; J Merlijn van den Berg; Taco W Kuijpers Journal: Eur Radiol Date: 2013-10-08 Impact factor: 5.315
Authors: A N Colebatch-Bourn; C J Edwards; P Collado; M-A D'Agostino; R Hemke; S Jousse-Joulin; M Maas; A Martini; E Naredo; M Østergaard; M Rooney; N Tzaribachev; M A van Rossum; J Vojinovic; P G Conaghan; C Malattia Journal: Ann Rheum Dis Date: 2015-08-05 Impact factor: 19.103
Authors: Joachim Gerss; Monika Tedy; Ariane Klein; Gerd Horneff; Maria Miranda-Garcia; Christoph Kessel; Dirk Holzinger; Valda Stanevica; Joost F Swart; David A Cabral; Hermine I Brunner; Dirk Foell Journal: Ann Rheum Dis Date: 2022-03-08 Impact factor: 27.973
Authors: Daniel B Horton; Jomaira Salas; Aleksandra Wec; Melanie Kohlheim; Pooja Kapadia; Timothy Beukelman; Alexis Boneparth; Ky Haverkamp; Melissa L Mannion; L Nandini Moorthy; Sarah Ringold; Marsha Rosenthal Journal: Arthritis Care Res (Hoboken) Date: 2021-03 Impact factor: 4.794